Envue Medical Q2 FY26 net loss widens 23% to $4.9 million; revenue falls 51.6% to $239,000

• Envue Medical posted a net loss of USD 4.9 million for the quarter ended June 30, 2026, widening 23%.
• Revenue fell 51.6% to USD 239, due to a PainShield/UroShield production halt tied to the war in Israel.
• Gross loss widened to USD 266, on USD 140 of ENvue-merger amortization, discounted ENvue system sales, and a USD 41 inventory write-down.
• Selling and marketing expenses climbed 78% to USD 1.2 million, driven by ENvue commercialization and UroShield expansion into the U.K.
• Cash and cash equivalents totaled USD 1.08 million; management flagged substantial doubt about going concern over the next 12 months.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Envue Medical Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-038778), on August 17, 2026, and is solely responsible for the information contained therein.